229 related articles for article (PubMed ID: 24799066)
21. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors.
Mikkers H; Nawijn M; Allen J; Brouwers C; Verhoeven E; Jonkers J; Berns A
Mol Cell Biol; 2004 Jul; 24(13):6104-15. PubMed ID: 15199164
[TBL] [Abstract][Full Text] [Related]
22. The PIM family of serine/threonine kinases in cancer.
Narlik-Grassow M; Blanco-Aparicio C; Carnero A
Med Res Rev; 2014 Jan; 34(1):136-59. PubMed ID: 23576269
[TBL] [Abstract][Full Text] [Related]
23. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.
Blanco-Aparicio C; Carnero A
Biochem Pharmacol; 2013 Mar; 85(5):629-643. PubMed ID: 23041228
[TBL] [Abstract][Full Text] [Related]
24. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
25. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.
Morishita D; Katayama R; Sekimizu K; Tsuruo T; Fujita N
Cancer Res; 2008 Jul; 68(13):5076-85. PubMed ID: 18593906
[TBL] [Abstract][Full Text] [Related]
26. [Pim-1 induced by hypoxia is involved in drug resistance and tumorigenesis of solid tumor cells].
Teh BG
Hokkaido Igaku Zasshi; 2004 Jan; 79(1):19-26. PubMed ID: 14978971
[No Abstract] [Full Text] [Related]
27. T-18, a stemonamide synthetic intermediate inhibits Pim kinase activity and induces cell apoptosis, acting as a potent anticancer drug.
Wang Z; Li XM; Shang K; Zhang P; Wang CF; Xin YH; Zhou L; Li YY
Oncol Rep; 2013 Mar; 29(3):1245-51. PubMed ID: 23314349
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA‑506 participates in pancreatic cancer pathogenesis by targeting PIM3.
Du J; Zheng X; Cai S; Zhu Z; Tan J; Hu B; Huang Z; Jiao H
Mol Med Rep; 2015 Oct; 12(4):5121-6. PubMed ID: 26238203
[TBL] [Abstract][Full Text] [Related]
29. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway.
Lilly M; Sandholm J; Cooper JJ; Koskinen PJ; Kraft A
Oncogene; 1999 Jul; 18(27):4022-31. PubMed ID: 10435626
[TBL] [Abstract][Full Text] [Related]
30. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.
Schatz JH; Oricchio E; Wolfe AL; Jiang M; Linkov I; Maragulia J; Shi W; Zhang Z; Rajasekhar VK; Pagano NC; Porco JA; Teruya-Feldstein J; Rosen N; Zelenetz AD; Pelletier J; Wendel HG
J Exp Med; 2011 Aug; 208(9):1799-807. PubMed ID: 21859846
[TBL] [Abstract][Full Text] [Related]
31. Roles of Pim-3, a novel survival kinase, in tumorigenesis.
Mukaida N; Wang YY; Li YY
Cancer Sci; 2011 Aug; 102(8):1437-42. PubMed ID: 21518143
[TBL] [Abstract][Full Text] [Related]
32. Pim-2 Modulates Aerobic Glycolysis and Energy Production during the Development of Colorectal Tumors.
Zhang XH; Yu HL; Wang FJ; Han YL; Yang WL
Int J Med Sci; 2015; 12(6):487-93. PubMed ID: 26078709
[TBL] [Abstract][Full Text] [Related]
33. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis.
Wang Z; Bhattacharya N; Weaver M; Petersen K; Meyer M; Gapter L; Magnuson NS
J Vet Sci; 2001 Dec; 2(3):167-79. PubMed ID: 12441685
[TBL] [Abstract][Full Text] [Related]
34. Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.
Białopiotrowicz E; Górniak P; Noyszewska-Kania M; Puła B; Makuch-Łasica H; Nowak G; Bluszcz A; Szydłowski M; Jabłonska E; Piechna K; Sewastianik T; Polak A; Lech-Marańda E; Budziszewska BK; Wasylecka-Juszczyńska M; Borg K; Warzocha K; Czardybon W; Gałęzowski M; Windak R; Brzózka K; Juszczyński P
J Cell Mol Med; 2018 Jul; 22(7):3548-3559. PubMed ID: 29665227
[TBL] [Abstract][Full Text] [Related]
35. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
[TBL] [Abstract][Full Text] [Related]
36. Identification of stemonamide synthetic intermediates as a novel potent anticancer drug with an apoptosis-inducing ability.
Li YY; Wang YY; Taniguchi T; Kawakami T; Baba T; Ishibashi H; Mukaida N
Int J Cancer; 2010 Jul; 127(2):474-84. PubMed ID: 19921695
[TBL] [Abstract][Full Text] [Related]
37. Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer.
Valdman A; Fang X; Pang ST; Ekman P; Egevad L
Prostate; 2004 Sep; 60(4):367-71. PubMed ID: 15264249
[TBL] [Abstract][Full Text] [Related]
38. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.
Forshell LP; Li Y; Forshell TZ; Rudelius M; Nilsson L; Keller U; Nilsson J
Oncotarget; 2011 Jun; 2(6):448-60. PubMed ID: 21646687
[TBL] [Abstract][Full Text] [Related]
39. PIM kinases 1, 2 and 3 in intracellular LIF signaling, proliferation and apoptosis in trophoblastic cells.
Mary Photini S; Chaiwangyen W; Weber M; Al-Kawlani B; Favaro RR; Jeschke U; Schleussner E; Morales-Prieto DM; Markert UR
Exp Cell Res; 2017 Oct; 359(1):275-283. PubMed ID: 28729093
[TBL] [Abstract][Full Text] [Related]
40. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
